Ayman Al-Hendy MD
Professor, Obstetrics & Gynecology, University of Chicago
Join to View Full Profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Dr. Al-Hendy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Zagazig University Faculty of MedicineClass of 1986
Certifications & Licensure
IL State Medical License 2017 - 2026
GA State Medical License 2013 - 2019
FL State Medical License 2012 - 2016
PA State Medical License 2012 - 2016
TN State Medical License 2007 - 2016
TX State Medical License 2002 - 2013
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
Clinical Trials
- Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids Start of enrollment: 2010 Dec 01
- Rejuvenation of Premature Ovarian Failure With Stem Cells Start of enrollment: 2016 Feb 06
- Pharmacokinetics and Hepatic Safety of EGCG Start of enrollment: 2020 Nov 24
- Join now to see all
Publications & Presentations
PubMed
- Uterine fibroids - why you should choose tailored therapies based on the joint decision of the physician and the patient.Michal Ciebiera, Tomasz Lozinski, Ayman Al-Hendy
Ginekologia Polska. 2025-07-25 - Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions.Mervat M Omran, Somayeh Vafaei, Samar Alkhrait, Qiwei Yang, Ayman Al-Hendy
Journal of Cellular and Molecular Medicine. 2025-06-01 - Fibroids and Health Equity: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.Amy C Taylor, Erica E Marsh, Elizabeth A Stewart, Ayman Al-Hendy, Lauren A Wise
Journal of Vascular and Interventional Radiology. 2025-05-27
Press Mentions
Altin Biosciences Announces US Patent Approval for Its First-in-Class, Non-Hormonal, Oral Botanical Drug CandidateJune 25th, 2025- ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific MeetingMay 8th, 2022
- Uterine Fibroids: Assessing Unmet Needs from Bench to BedsideAugust 17th, 2021
- Join now to see all
Grant Support
- Pathological reprogramming of the m6A epitranscriptome in uterine fibroidsUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2021–2026
- 3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroidsUNIVERSITY OF ILLINOIS AT CHICAGO2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
